Owner assessment of therapeutic interventions for canine atopic dermatitis: a long‐term retrospective analysis

Dell, Darin L.; Griffin, Craig E.; Thompson, Lori A.; Griffies, Joel D.

doi:10.1111/j.1365-3164.2012.01054.x

Cited by 26 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Withdrawal of oral glucocorticoid treatment was achieved after Allermmune â HDM therapy in six cases (46.2%), suggesting higher response rates compared to those of previous reports on ASIT (5.0-21.5%). [14][15][16][17][18] Allermmune â HDM contains the recombinant mite allergen (Der f 2) manufactured by expressing Der f 2, a major mite allergen protein of CAD, in silkworms. The purified Der f 2 is then conjugated with pullulan (forming Der f 2-P).…”

Section: Discussionmentioning

confidence: 99%

A pilot study of the effect of pullulan‐conjugated Der f 2 allergen‐specific immunotherapy on canine atopic dermatitis

Kawano

Mizuno

2017

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A pilot study of the effect of pullulan‐conjugated Der f 2 allergen‐specific immunotherapy on canine atopic dermatitis

Kawano

Mizuno

2017

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

“…Many dogs on AIT in this study received concurrent antipruritic therapy. Multimodal therapy is commonly needed in canine atopic dermatitis (4,24,25). However, after rush AIT in most dogs those were restricted to medications with few and mild adverse effects.…”

Section: Tab 4 üBerblick Zur Medikationmentioning

confidence: 99%

Efficacy and safety of rush immunotherapy with alumprecipitated allergens in canine atopic dermatitis

Hobi¹,

Mueller²

2014

Tierarztl Prax Ausg K

View full text Add to dashboard Cite

Summary Objectives: Canine atopic dermatitis is a very common disease in small animal practice. Its only specific treatment is allergen immunotherapy. In rush-immunotherapy (RIT) increasing doses of allergen extract are injected subcutaneously in short intervals. Maintenance doses are achieved within one day compared to weeks or months with conventional immunotherapy. The aim of this study was to evaluate the safety and efficacy of RIT with alum-precipitated allergens. Materials and methods: A series of 20 dogs with atopic dermatitis underwent RIT with alum-precipitated allergens. Pruritus and medications at the start of the immunotherapy and 12 months afterwards were compared and adverse effects were recorded. Results: Significant improvement in pruritus (p = 0.0001) and medication scores (p = 0.0004) was noted after approximately 12 months of treatment. The observed clinical response was good to excellent in 70% of the dogs, consistent with other published reports. One dog vomited once during the induction day, with no other clinical problems and completion of the normal protocol. The other 19 dogs showed no adverse effects at all during or after RIT. Conclusion and clinical relevance: RIT with alum-precipitated allergens seems to be a safe and efficacious method to treat dogs with atopic dermatitis.

show abstract

“…There is no evidence supporting the use of topical type 1 antihistamine formulations to treat canine AD (SOR C). Basis for such recommendations: Approximately 25 % of clients that gave oral antihistamines to their atopic dogs reported these to be at least very effective in a retrospective survey (QOE 2) [ 15 ]. An RCT reported that two oral antihistamines, a hydroxyzine and chlorpheniramine combination (Histacalmine, Virbac) and dimetindene (Fenistil, Novartis), mildly improved pruritus and skin lesions in dogs with AD (QOE 2) [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

et al. 2015

View full text Add to dashboard Cite

BackgroundIn 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document.ResultsThe treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD.ConclusionsThis first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.Electronic supplementary materialThe online version of this article (doi:10.1186/s12917-015-0514-6) contains supplementary material, which is available to authorized users.

show abstract

Owner assessment of therapeutic interventions for canine atopic dermatitis: a long‐term retrospective analysis

Cited by 26 publications

References 20 publications

A pilot study of the effect of pullulan‐conjugated Der f 2 allergen‐specific immunotherapy on canine atopic dermatitis

A pilot study of the effect of pullulan‐conjugated Der f 2 allergen‐specific immunotherapy on canine atopic dermatitis

Efficacy and safety of rush immunotherapy with alumprecipitated allergens in canine atopic dermatitis

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

Contact Info

Product

Resources

About